ReviewFrontiers in endocrinology2026
Obesity and type 2 diabetes as chronic inflammation: how does the cytokine evidence align?
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Follicular Immune Checkpoint: PD-1/PD-L1 and Immune Tolerance in Oocyte Competence and IVF Failure.International journal of molecular sciences · 2026Review
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Inflammatory Load Across Diabetes Duration: CRP and ESR Patterns and Their Metabolic Correlates.Metabolites · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global epidemic and a major risk factor for several non-communicable diseases. Systemic inflammation is believed to be involved in obesity and obesity-induced diabetes type 2, which alters adipose tissue homeostasis. Cytokines, the key mediators of inflammation, play a central role in this inflammatory state and have been extensively studied for their role in obesity and diabetes type 2. Therefore, blood and adipose tissue levels of cytokines have been a subject of intense investigation over the last two decades. Several studies reveal the role of cytokines and their profiles in the obese population. These studies have reported the significance of altered levels and patterns of several cytokines and their association with clinical parameters in obese and type 2 diabetics. This review examines population-based studies to evaluate whether cytokine profile consistently reflect chronic inflammation in obesity and type 2 diabetes. It highlights cytokines that show robust associations across ethnic and geographic cohorts. While majority of cytokines are frequently elevated in both conditions, their predictive value remains unclear. On the contrary we do find inflammatory cytokines like IL-1β which shows an association with diabetes type 2 but not obesity while IL-6 is more closely associated with obesity than diabetes. Anti-inflammatory cytokines IL-10 and IL-4 cannot be linked to either conditions. The study underscores the need for longitudinal and mechanistic studies to determine whether cytokine profiling could be used as an early diagnostic or prognostic tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.